Immediate Impact
2 standout
Citing Papers
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
2025 Standout
Nanoparticles in Clinical Translation for Cancer Therapy
2022 Standout
Works of Michael R. Schoen being referenced
A randomized, double-blind, placebo-controlled, multicenter, binational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Michael R. Schoen | 5 | 3 | 12 | 8 | 4 | 17 | |
| Pamela Cooper | 4 | 4 | 13 | 3 | 5 | 14 | |
| Yurii Ostapenko | 2 | 4 | 8 | 8 | 4 | 15 | |
| Osama Mohamed Elsanousi | 4 | 2 | 5 | 7 | 4 | 13 | |
| Alexander Olkus | 9 | 3 | 6 | 10 | 4 | 16 | |
| HarveyM. Golomb | 3 | 7 | 7 | 2 | 4 | 19 | |
| Paul J. Needham | 9 | 3 | 3 | 9 | 4 | 13 | |
| Luis Manuel Domínguez-Parra | 5 | 8 | 7 | 2 | 2 | 14 | |
| M. Schmit | 5 | 2 | 8 | 2 | 4 | 21 | |
| Ekaterina Zhuravleva | 5 | 7 | 4 | 2 | 5 | 15 | |
| Radhakrishnan Hariraj | 5 | 2 | 4 | 2 | 5 | 19 |
All Works
Loading papers...